Structural analysis shows Alzheimer's disease mutation produces 'cottonwool' structures in the brain
An international collaboration led by RIKEN researchers has discovered how unusual spherical structures form in the brains of ...
Armed robbery in Revesby14h
Alzheimer's Mutation Forms Cottonwool Brain Structures
Figure 1: A new W-shaped structural model of E22G 40-residue beta-amyloid fibrils. RIKEN researchers have shown how the ...
Pharmaceutical Technology1h
EMA rethinks stance, committee now recommends Leqembi for Alzheimer’s disease
Following a re-evaluation, the EMA has recommended Eisai and Biogen’s Alzheimer’s therapy Leqembi for a subgroup of patients.
News Medical on MSN9d
New Alzheimer's guidelines focus on risk, not diagnosis, in healthy adults
Researchers from the International Working Group recommend categorizing biomarker-positive, cognitively normal individuals as ...
University of Delaware23h
New Alzheimer’s insights
A new interdisciplinary study at the University of Delaware seeks to study AD by examining changes in the arteries and brain ...
Too Old to Operate9d
Cerebral Amyloid Angiopathy Mediated by CERAD and Braak Staging
The following is a summary of “Cerebral Amyloid Angiopathy, Dementia, and Alzheimer Neuropathologic Changes: Findings From ...
IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
POTOMAC, MD / ACCESSWIRE / November 14, 2024 / IGC Pharma, Inc. ('IGC' or the 'Company') (NYSE American:IGC) today announced its financial ...
GEN13d
Alzheimer’s Nerve Cell Death May Be Preventable by Halting Necroptosis
Specific inhibitors that could prevent the loss of nerve cells in different mouse models of Alzheimer's disease uncovered.
FDA Authorizes The First AI-Driven MRI Solution For Safer Alzheimer's Treatment
"Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer's disease but they are associated ...
BioSpace3d
Leqembi, Kisunla and Beyond: The Next Wave of Alzheimer’s at CTAD 2024
With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...
UK’s NICE Says Alzheimer’s Disease Drug Kisunla Is Not Cost-Effective
The Alzheimer's disease drug Kisunla will face major reimbursement challenges in the U.K. after the cost-effectiveness watchdog, NICE, said the drug isn't cost-effective.